{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:17:32Z","timestamp":1791065852554,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T00:00:00Z","timestamp":1373500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jhep.2013.07.014","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T12:32:36Z","timestamp":1373891556000},"page":"1323-1330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations"],"prefix":"10.1016","volume":"59","author":[{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.07.014_b0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"Clinical practice guidelines: management of hepatitis C virus infection","volume":"55","author":"EASL","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0015","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.014_b0020","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.014_b0025","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment or hepatitis C virus infection","volume":"364","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.014_b0030","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.014_b0035","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.014_b0040","first-page":"217A","article-title":"ANRS CO20 CUPIC study group. Safety of telaprevir or boceprevir in combination with peginterferon alfa\/ribavirin, in cirrhotic non-responders. Week 16 analysis of the French early access program in real life setting","volume":"56","author":"Hezode","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0045","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1572-0241.2008.01957.x","article-title":"Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon-alfa-2a (40KD) plus ribavirin","volume":"103","author":"Reau","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.07.014_b0050","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","article-title":"ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C","volume":"464","author":"Fellay","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2013.07.014_b0055","first-page":"564A","article-title":"Factors predictive of anemia development in treatment-experienced patients receiving telaprevir (T; TVR) plus peginterferon\/ribavirin (PR) in the REALIZE trial","volume":"56","author":"Zeuzem","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0060","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/S0168-8278(12)61430-5","article-title":"A randomized trial comparing ribavirin dose reduction vs. erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon\/ribavirin","volume":"56","author":"Poordad","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0065","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon alfa-2b\/ribavirin and boceprevir: analysis from the SPRINT-2 trial","volume":"57","author":"Sulkowski","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0070","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2013.07.014_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dld.2012.05.002","article-title":"Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials","volume":"45","author":"Aghemo","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2013.07.014_b0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1053\/j.gastro.2010.06.016","article-title":"Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.07.014_b0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2012.11.027","article-title":"Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection","volume":"58","author":"Rau","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.24058","article-title":"Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir","volume":"53","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","article-title":"IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C","volume":"204","author":"Chayama","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2013.07.014_b0100","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/S0168-8278(12)61174-X","article-title":"Ribavirin dose modification in treatment-na\u00efve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3","volume":"56","author":"Sulkowski","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0110","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1053\/j.gastro.2010.07.059","article-title":"Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate","volume":"139","author":"Sulkowski","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.07.014_b0115","first-page":"216A","article-title":"Boceprevir (BOC) combined with peginterferon alfa-2b\/ribavirin (P\/RBV) in treatment-na\u00efve chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response (SVR) and safety subanalyses from the Anemia Management Study","volume":"56","author":"Lawitz","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0120","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue","year":"1999","journal-title":"Semin Liv Dis"},{"key":"10.1016\/j.jhep.2013.07.014_b0125","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2010-08-300541","article-title":"American society of hematology\/American society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"116","author":"Rizzo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2013.07.014_b0130","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1155\/2006\/497059","article-title":"Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin","volume":"20","author":"Sherman","year":"2006","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2013.07.014_b0135","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0140","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2013.07.014_b0145","first-page":"CD006803","article-title":"Antiviral therapy for recurrent liver graft infection with hepatitis C virus","volume":"20","author":"Gurusamy","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2013.07.014_b0150","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/lt.21184","article-title":"Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C","volume":"13","author":"Saab","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.07.014_b0155","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/lt.22387","article-title":"Anemia is not predictive of sustained viral response in HCV-liver transplant recipients treated with peg-interferon and ribavirin","volume":"17","author":"Giusto","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.07.014_b0160","first-page":"9A","article-title":"Efficacy and safety of protease inhibitors to treat Hepatitis C recurrence after liver transplantation: a first multicentric experience","volume":"56","author":"Coilly","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.014_b0165","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/S0168-8278(13)60808-9","article-title":"Management and outcomes of anemia in the international telaprevir early access program, for patients with hepatitis C genotype 1 infection","volume":"58","author":"Colombo","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.014_b0170","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2013.03.006","article-title":"Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C","volume":"11","author":"Belperio","year":"2013","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813004613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813004613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:28Z","timestamp":1759174348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813004613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0168827813004613"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.07.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2013.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}